KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.

Yan Huang, Dongchen Sun, Huaqiang Zhou, Ting Zhou, Song Qu, Jingao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Liangfang Shen, Hui Wu, Jinyi Lang, Guangyuan Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Bo Xie, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Feng Lei, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Shen Zhao, Gang Chen, Yaxiong Zhang, Yuanyuan Zhao, Wenfeng Fang, Chuanpei Huang, Xiaotong Li, Shaodong Hong, Li Zhang, Yunpeng Yang

JAMA Oncol 12(3) 295-302

PMID41609753
PMCIDPMC12856745
DOI10.1001/jamaoncol.2025.6245
发表日期2026-01-29
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

IMPORTANCE: Programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 inhibitors plus chemotherapy is the current standard first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). However, the long-term survival benefits at the 5-year benchmark remain uncertain. OBJECTIVE: To determine whether adding camrelizumab to chemotherapy significantly improved 5-year overall survival (OS) as first-line treatment for RM-NPC, compared with chemotherapy alone. DESIGN, SETTING, AND PARTICIPANTS: The CAPTAIN-1st trial was a randomized, double-blind, phase 3 trial conducted at 28 hospitals in China. Between November 13, 2018, and November 29, 2019, patients with treatment-naive RM-NPC were enrolled. This secondary analysis of the CAPTAIN-1st trial was prespecified. Data analysis was conducted on June 1, 2025. INTERVENTIONS: Patients were randomized (1:1) to receive camrelizumab or placebo in combination with gemcitabine and cisplatin for 4 to 6 cycles, followed by maintenance therapy with camrelizumab or placebo until disease progression, unacceptable toxic effects, or completion of 2 years of treatment. MAIN OUTCOME: The primary end point, progression-free survival per independent review committee, has been reported previously. Herein, the secondary end point of OS is reported as prespecified in the protocol. RESULTS: Among 263 randomized patients (134 in randomized to camrelizumab, 129 to placebo), baseline characteristics were generally balanced between groups, except for age. The mean (SD) age was 49 (11.25) years, and 218 patients (82.9%) were male individuals, 45 (17.1%) were female individuals. With a median survival follow-up of 63.5 (95% CI, 61.2-64.6) months for the camrelizumab group and 63.0 (95% CI, 60.8-64.6) months for the placebo group, 85 (63.4%) and 95 (73.6%) deaths occurred, respectively. Median OS was 34.5 months (95% CI, 29.4-45.7) with camrelizumab vs 26.6 months (95% CI, 19.8-33.5) with placebo (hazard ratio [HR], 0.74; 95% CI, 0.55-0.99; 2-sided P = .047). After adjusting for age imbalance, the HR was 0.65 (95% CI, 0.48-0.89; P = .01). The 5-year OS rates were 37.8% vs 24.2%, reflecting an absolute difference of 13.6% (95% CI, 2.4%-24.8%; P = .02) in favor of camrelizumab. The OS benefits were generally consistent across subgroups. In the camrelizumab group, patients who achieved rapid clearance of Epstein-Barr virus (EBV) DNA had significantly longer OS compared with those without EBV DNA clearance (HR, 0.32; 95% CI, 0.18-0.58; P < .001). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, the addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of RM-NPC. These findings provided the first 5-year evidence supporting the benefit of PD-1-based chemoimmunotherapy in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03707509.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2.. Overall Survival (OS) in the Intention-to-Treat Population Kaplan-Meier curves for OS at data cutoff at December 5, 2024. The hazard ratio (HR) was stratified by liver metastases, previous radical chemoradiotherapy, and Eastern Cooperative Oncology Group performance status. The dashed lines indicate median OS (50%) and 60-month OS.

Overall_Survival

Overall Survival

Figure 2 · Panel Overall_Survival

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Overall_Survival 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 4

Figure 4.. Overall Survival (OS) by Plasma Epstein-Barr Virus (EBV) DNA Clearance in the Camrelizumab Group Kaplan-Meier curves for OS in the camrelizumab group comparing patients who achieved plasma EBV DNA clearance in the first 3 treatment cycles vs those with persistently positive EBV DNA. The dashed lines indicate median OS and the corresponding time point.

Overall_Survival

OS

Figure 4 · Panel Overall_Survival

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Overall_Survival 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Trial Profile at the Final Analysis All patients who received at least 1 dose of camrelizumab/placebo, gemcitabine, or cisplatin were included in the analysis at data cutoff December 5, 2024.
非 KM Figure
Figure 3Figure 3.. Subgroup Analysis of Overall Survival (OS) Hazard ratios (HRs) and 95% CIs were estimated with unstratified Cox proportional hazards models. EBV indicates Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; NR, not reached; WHO, World Health Organization.
非 KM Figure